首页 > 最新文献

Innovations in clinical neuroscience最新文献

英文 中文
Patient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing. 患者在使用美沙酮治疗阿片类药物使用障碍中的挑战,以及对提高安全性和便利性的解决方案的看法。
Q3 Medicine Pub Date : 2024-12-01 eCollection Date: 2024-10-01
Eric Morse, Graeme Christianson, Melissa Olivadoti, John Timberlake

Background: Methadone is commonly utilized to treat opioid use disorder (OUD). Requirements to visit an opioid treatment provider (OTP) clinic for methadone treatment limits access to treatment, impacts quality of life, and reduces OUD treatment program retention. The Computerized Oral Prescription Administration (COPA) system is a dual-biometric dispensing device for take-home dosing that could reduce the impacts of methadone administration on patients and clinic staff.

Objective: To identify challenges for patients treated with methadone for OUD and gain their perspectives on COPA.

Methods: Adult patients treated with methadone at a single-site OTP clinic were recruited to complete a qualitative interview regarding their experience with methadone and the impact that expansion of take-home doses would have on their life. Participants were provided printed resources describing COPA and handled a COPA device before being asked for their perspectives.

Results: Participants (n=12) were 58.33 percent male and 41.67 percent female, and had no take-home doses (n=5), 2 to 5 days of take-home doses (n=4), or six or more days of take-home doses (n=3). Most (91.67%) participants desired more take-home doses, and 66.7 percent stated more take-home doses would reduce the negative impact of OUD treatment on their ability to work. Average time and cost per trip to obtain their methadone dose at the clinic was 75 minutes and $36.58, respectively. Participants responded positively toward COPA. Participants with no take-home privileges would pay $126.88 per month to obtain take-home privileges by using COPA, and those with take-home privileges would pay $30.31 per month to keep the same level of take-home doses and $117.50 per month to expand their take-home doses using COPA.

Conclusion: Participants endured a monetary and time burden to access their methadone treatment, and wished to have more take-home doses to reduce the frequency of their visits to the OTP clinic. Participants viewed take-home doses as having a positive impact on their ability to care for family members, hold a job, and travel, and they appreciated the key attributes of COPA and were willing to invest their own funds to gain access to the device. COPA is a potential solution to expand take-home methadone access to patients while ensuring safety, adherence, retention, and appropriate use.

背景:美沙酮通常用于治疗阿片类药物使用障碍(OUD)。要求前往阿片类药物治疗提供者(OTP)诊所进行美沙酮治疗限制了治疗的可及性,影响了生活质量,并减少了OUD治疗计划的保留。计算机化口服处方给药(COPA)系统是一种双生物识别配药装置,可以减少美沙酮给药对患者和临床工作人员的影响。目的:确定美沙酮治疗OUD患者面临的挑战,并获得他们对COPA的看法。方法:招募在单点OTP诊所接受美沙酮治疗的成年患者,对他们的美沙酮治疗经历和扩大带回家剂量对他们生活的影响进行定性访谈。在被问及他们的观点之前,向参与者提供了描述COPA的打印资源,并操作了COPA设备。结果:参与者(n=12)为58.33%的男性和41.67%的女性,没有带回家剂量(n=5), 2至5天的带回家剂量(n=4),或6天或更长时间的带回家剂量(n=3)。大多数(91.67%)参与者希望更多的带回家剂量,66.7%的人表示更多的带回家剂量会减少OUD治疗对他们工作能力的负面影响。每次在诊所获得美沙酮剂量的平均时间和费用分别为75分钟和36.58美元。参与者对COPA反应积极。没有带回家特权的参与者将每月支付126.88美元,通过使用COPA获得带回家特权,而那些有带回家特权的参与者将每月支付30.31美元以保持相同的带回家剂量水平,每月支付117.50美元以使用COPA扩大带回家剂量。结论:参与者承受了金钱和时间上的负担来获得他们的美沙酮治疗,并希望有更多的带回家剂量,以减少他们访问OTP诊所的频率。参与者认为带回家的剂量对他们照顾家庭成员、保持工作和旅行的能力有积极的影响,他们欣赏COPA的关键属性,并愿意投入自己的资金来获得设备。COPA是一种潜在的解决方案,可以在确保安全性、依从性、保留性和适当使用的同时,扩大患者可带回家的美沙酮。
{"title":"Patient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing.","authors":"Eric Morse, Graeme Christianson, Melissa Olivadoti, John Timberlake","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Methadone is commonly utilized to treat opioid use disorder (OUD). Requirements to visit an opioid treatment provider (OTP) clinic for methadone treatment limits access to treatment, impacts quality of life, and reduces OUD treatment program retention. The Computerized Oral Prescription Administration (COPA) system is a dual-biometric dispensing device for take-home dosing that could reduce the impacts of methadone administration on patients and clinic staff.</p><p><strong>Objective: </strong>To identify challenges for patients treated with methadone for OUD and gain their perspectives on COPA.</p><p><strong>Methods: </strong>Adult patients treated with methadone at a single-site OTP clinic were recruited to complete a qualitative interview regarding their experience with methadone and the impact that expansion of take-home doses would have on their life. Participants were provided printed resources describing COPA and handled a COPA device before being asked for their perspectives.</p><p><strong>Results: </strong>Participants (n=12) were 58.33 percent male and 41.67 percent female, and had no take-home doses (n=5), 2 to 5 days of take-home doses (n=4), or six or more days of take-home doses (n=3). Most (91.67%) participants desired more take-home doses, and 66.7 percent stated more take-home doses would reduce the negative impact of OUD treatment on their ability to work. Average time and cost per trip to obtain their methadone dose at the clinic was 75 minutes and $36.58, respectively. Participants responded positively toward COPA. Participants with no take-home privileges would pay $126.88 per month to obtain take-home privileges by using COPA, and those with take-home privileges would pay $30.31 per month to keep the same level of take-home doses and $117.50 per month to expand their take-home doses using COPA.</p><p><strong>Conclusion: </strong>Participants endured a monetary and time burden to access their methadone treatment, and wished to have more take-home doses to reduce the frequency of their visits to the OTP clinic. Participants viewed take-home doses as having a positive impact on their ability to care for family members, hold a job, and travel, and they appreciated the key attributes of COPA and were willing to invest their own funds to gain access to the device. COPA is a potential solution to expand take-home methadone access to patients while ensuring safety, adherence, retention, and appropriate use.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"25-33"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schizophrenia with catatonia and stupor is an emergency and requires immediate psychiatric and neurological evaluation. 精神分裂症伴紧张症和昏迷是一种紧急情况,需要立即进行精神病学和神经学评估。
Q3 Medicine Pub Date : 2024-12-01 eCollection Date: 2024-10-01
Josef Finsterer
{"title":"Schizophrenia with catatonia and stupor is an emergency and requires immediate psychiatric and neurological evaluation.","authors":"Josef Finsterer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in the Geriatric Population. 选择性血清素再摄取抑制剂与老年人群出血风险。
Q3 Medicine Pub Date : 2024-12-01 eCollection Date: 2024-10-01
Nitin Pothen, Prachi Patel, Aneela Jafri

Introduction: The demographics of the United States (US) are evolving as time progresses. The geriatric population is growing, with many elderly people dealing with mental health issues. Major depressive episodes affect 1 to 5 percent of those aged 65 years or older, which emphasizes the importance of addressing mental health concerns in this populace. This article explores how antidepressant use can lead to bleeding problems in geriatric patients, as the prevalence of treatment-resistant depression in these patients is increasing, along with the identification of the potentially life-threatening bleeding risks associated with these medications.

Methods: We did a comprehensive literature search using PubMed, EBSCOhost, and Google Scholar to find the articles pertinent to our subject. Reference lists of relevant articles were also reviewed.

Conclusion: These findings highlight the heightened risk of severe bleeding events linked to use of selective serotonin reuptake inhibitors (SSRIs) in the elderly. This was most notable among octogenarians and those with a history of upper gastrointestinal (GI) bleeding. This risk is accentuated when SSRIs are combined with antiplatelet drugs and nonsteroidal anti-inflammatory drugs (NSAIDs), the highest risk being observed with use of a combination of aspirin, clopidogrel, and SSRIs. Our review concludes that while the relative risk is high, the absolute risk remains low. However, caution is advised when prescribing SSRIs to individuals aged 80 years or older. These findings emphasize the need for tailored medication management, vigilant monitoring, and a patient-centered approach in prescribing antidepressants to geriatric patients. Balancing mental healthcare with potential bleeding risks is paramount in the evolving landscape of geriatric mental health.

导读:随着时间的推移,美国的人口结构也在发生变化。老年人口正在增长,许多老年人面临心理健康问题。在65岁或以上的人群中,有1%到5%的人患有重度抑郁症,这就强调了解决这一人群心理健康问题的重要性。这篇文章探讨了抗抑郁药的使用如何导致老年患者出血问题,因为这些患者中治疗难治性抑郁症的患病率正在增加,以及与这些药物相关的潜在危及生命的出血风险的确定。方法:我们使用PubMed, EBSCOhost和b谷歌Scholar进行全面的文献检索,找到与我们主题相关的文章。还审查了相关文章的参考文献清单。结论:这些发现强调了老年人使用选择性血清素再摄取抑制剂(SSRIs)会增加严重出血事件的风险。这在80多岁老人和有上消化道出血史的人群中最为显著。当SSRIs与抗血小板药物和非甾体抗炎药(NSAIDs)联合使用时,这种风险增加,阿司匹林、氯吡格雷和SSRIs联合使用的风险最高。我们的结论是,虽然相对风险很高,但绝对风险仍然很低。然而,在给80岁或以上的人开SSRIs处方时,建议谨慎。这些发现强调了在给老年患者开抗抑郁药处方时需要量身定制的药物管理、警惕的监测和以患者为中心的方法。平衡心理保健与潜在的出血风险在老年心理健康的不断发展的景观是至关重要的。
{"title":"Selective Serotonin Reuptake Inhibitors and Bleeding Risk in the Geriatric Population.","authors":"Nitin Pothen, Prachi Patel, Aneela Jafri","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>The demographics of the United States (US) are evolving as time progresses. The geriatric population is growing, with many elderly people dealing with mental health issues. Major depressive episodes affect 1 to 5 percent of those aged 65 years or older, which emphasizes the importance of addressing mental health concerns in this populace. This article explores how antidepressant use can lead to bleeding problems in geriatric patients, as the prevalence of treatment-resistant depression in these patients is increasing, along with the identification of the potentially life-threatening bleeding risks associated with these medications.</p><p><strong>Methods: </strong>We did a comprehensive literature search using PubMed, EBSCOhost, and Google Scholar to find the articles pertinent to our subject. Reference lists of relevant articles were also reviewed.</p><p><strong>Conclusion: </strong>These findings highlight the heightened risk of severe bleeding events linked to use of selective serotonin reuptake inhibitors (SSRIs) in the elderly. This was most notable among octogenarians and those with a history of upper gastrointestinal (GI) bleeding. This risk is accentuated when SSRIs are combined with antiplatelet drugs and nonsteroidal anti-inflammatory drugs (NSAIDs), the highest risk being observed with use of a combination of aspirin, clopidogrel, and SSRIs. Our review concludes that while the relative risk is high, the absolute risk remains low. However, caution is advised when prescribing SSRIs to individuals aged 80 years or older. These findings emphasize the need for tailored medication management, vigilant monitoring, and a patient-centered approach in prescribing antidepressants to geriatric patients. Balancing mental healthcare with potential bleeding risks is paramount in the evolving landscape of geriatric mental health.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"34-37"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sociodemographic Factors and Consanguinity in Intellectual Disability: A Pilot Study. 智力残疾的社会人口因素与血缘关系:一项初步研究。
Q3 Medicine Pub Date : 2024-12-01 eCollection Date: 2024-10-01
Yousra Benmakhlouf, Achraf Laghmich, Kaoutar Ben Makhlouf, Amina Barakat, Naima Ghailani Nourouti, Mohcine Bennani Mechita

Objective: Arab populations have a long tradition of consanguinity. In Morocco, consanguineous marriages are culturally favored. In this study, we assessed the effect of consanguinity on the occurrence of intellectual disability (ID) and investigated its association to education level and professional status in a series of Moroccan families.

Design: In total, 186 patients with ID were included in this study. Data were processed and analyzed with the IBM SPSS.

Results: The rate of consanguinity among the parents of children with ID was 34.95 percent. Marriages between first cousins accounted for 24.19 percent of consanguineous unions (FI=0.02). In the general population (n=300), 27.3 percent of marriages were consanguineous, with 22.66 percent being marriages between first cousins. Marriage between first cousins was the most common type of consanguineous marriage. The illiteracy rate was greater among women, compared to men (56.9% vs. 37.87%). The majority of mothers (81.11%) were housewives. A predominance of low professional status was observed among the men (62.22% of population, 22.7%). There was a high correlation between consanguinity and ID. The association between education level, professional status, and consanguinity rate in ID was not statistically significant (p>0.05).

Conclusion: The consanguinity rate in Moroccan families remains important. More strategies and efforts must be taken and reinforced for a better understanding and awareness of consanguinity risks to significantly reduce this practice.

目的:阿拉伯人口有着悠久的血缘传统。在摩洛哥,近亲婚姻在文化上是受欢迎的。在本研究中,我们评估了血缘关系对智力残疾(ID)发生的影响,并调查了其与一系列摩洛哥家庭的教育水平和职业地位的关系。设计:本研究共纳入186例ID患者。采用IBM SPSS软件对数据进行处理和分析。结果:患儿父母有血缘关系的比例为34.95%。近亲结婚的比率为24.19% (FI=0.02)。在普通人群(n=300)中,27.3%的婚姻是近亲婚姻,其中22.66%是近亲婚姻。表亲之间的婚姻是最常见的近亲婚姻。女性的文盲率高于男性(56.9%对37.87%)。大多数母亲(81.11%)是家庭主妇。男性以低职业地位为主(62.22%,22.7%)。血缘关系和身份之间有很高的相关性。受教育程度、职业地位与血缘率之间的相关性无统计学意义(p < 0.05)。结论:摩洛哥家庭的血亲率仍然很重要。必须采取和加强更多的战略和努力,以更好地了解和认识亲属风险,从而大大减少这种做法。
{"title":"Sociodemographic Factors and Consanguinity in Intellectual Disability: A Pilot Study.","authors":"Yousra Benmakhlouf, Achraf Laghmich, Kaoutar Ben Makhlouf, Amina Barakat, Naima Ghailani Nourouti, Mohcine Bennani Mechita","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Arab populations have a long tradition of consanguinity. In Morocco, consanguineous marriages are culturally favored. In this study, we assessed the effect of consanguinity on the occurrence of intellectual disability (ID) and investigated its association to education level and professional status in a series of Moroccan families.</p><p><strong>Design: </strong>In total, 186 patients with ID were included in this study. Data were processed and analyzed with the IBM SPSS.</p><p><strong>Results: </strong>The rate of consanguinity among the parents of children with ID was 34.95 percent. Marriages between first cousins accounted for 24.19 percent of consanguineous unions (FI=0.02). In the general population (n=300), 27.3 percent of marriages were consanguineous, with 22.66 percent being marriages between first cousins. Marriage between first cousins was the most common type of consanguineous marriage. The illiteracy rate was greater among women, compared to men (56.9% vs. 37.87%). The majority of mothers (81.11%) were housewives. A predominance of low professional status was observed among the men (62.22% of population, 22.7%). There was a high correlation between consanguinity and ID. The association between education level, professional status, and consanguinity rate in ID was not statistically significant (<i>p</i>>0.05).</p><p><strong>Conclusion: </strong>The consanguinity rate in Moroccan families remains important. More strategies and efforts must be taken and reinforced for a better understanding and awareness of consanguinity risks to significantly reduce this practice.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Levels of Vitamin D, Beta-Amyloid 42, Indoxyl Sulfate, and Serum Parathyroid Hormone in Hemodialysis Patients with Cognitive Impairment. 血液透析伴认知障碍患者血清维生素D、β -淀粉样蛋白42、硫酸吲哚酚和甲状旁腺激素水平分析
Q3 Medicine Pub Date : 2024-12-01 eCollection Date: 2024-10-01
Yuliarni Syafrita, Harnavi Harun, Restu Susanti, Syarif Indra

Objective: Cognitive impairment is a recurrent complication in people with chronic kidney disease (CKD), which includes those undergoing hemodialysis (HD). Researchers aimed to analyze vitamin D levels, beta-amyloid 42, indoxyl sulfate, and serum parathyroid hormone (PTH) in patients with cognitive impairment who underwent HD.

Design: This comparative, cross-sectional study was conducted at the HD unit of Dr. M Djamil Padang Hospital. This study enrolled 60 patients with CKD who underwent routine HD and 20 normal subjects as controls. In both groups, serum levels of vitamin D, beta-amyloid 42, indoxyl sulfate, and PTH were measured using the enzyme-linked immunosorbent assay method, and cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment neuropsychological test.

Results: The mean±standard deviation age of the study subjects was 51.48±11.44 years, with 53.4 percent being male. Vitamin D levels were higher in the control group, compared to the case group (p<0.05). The case group had higher levels of beta-amyloid, indoxyl sulfate, and PTH, compared to the control group (p<0.05). Significant differences were found in vitamin D and indoxyl sulfate levels between the groups with and without cognitive impairment (p<0.05).

Conclusion: Lower levels of vitamin D and higher levels of indoxyl sulfate were observed in the group with cognitive impairment when compared to the group without cognitive impairment.

目的:认知障碍是慢性肾脏疾病(CKD)患者的复发性并发症,包括接受血液透析(HD)的患者。研究人员旨在分析患有认知障碍的HD患者的维生素D水平、β -淀粉样蛋白42、硫酸吲哚酚和血清甲状旁腺激素(PTH)。设计:这项比较的横断面研究是在Dr. M Djamil Padang医院的HD部门进行的。这项研究招募了60名CKD患者,他们接受了常规的HD治疗,20名正常受试者作为对照。在两组中,使用酶联免疫吸附法测量血清维生素D、β -淀粉样蛋白42、硫酸吲哚酚和甲状旁腺激素水平,并使用印度尼西亚版的蒙特利尔认知评估神经心理测试评估认知功能。结果:研究对象的平均±标准差年龄为51.48±11.44岁,男性占53.4%。结论:与无认知障碍组相比,认知障碍组的维生素D水平较低,硫酸吲哚酚水平较高。
{"title":"Analysis of Levels of Vitamin D, Beta-Amyloid 42, Indoxyl Sulfate, and Serum Parathyroid Hormone in Hemodialysis Patients with Cognitive Impairment.","authors":"Yuliarni Syafrita, Harnavi Harun, Restu Susanti, Syarif Indra","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Cognitive impairment is a recurrent complication in people with chronic kidney disease (CKD), which includes those undergoing hemodialysis (HD). Researchers aimed to analyze vitamin D levels, beta-amyloid 42, indoxyl sulfate, and serum parathyroid hormone (PTH) in patients with cognitive impairment who underwent HD.</p><p><strong>Design: </strong>This comparative, cross-sectional study was conducted at the HD unit of Dr. M Djamil Padang Hospital. This study enrolled 60 patients with CKD who underwent routine HD and 20 normal subjects as controls. In both groups, serum levels of vitamin D, beta-amyloid 42, indoxyl sulfate, and PTH were measured using the enzyme-linked immunosorbent assay method, and cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment neuropsychological test.</p><p><strong>Results: </strong>The mean±standard deviation age of the study subjects was 51.48±11.44 years, with 53.4 percent being male. Vitamin D levels were higher in the control group, compared to the case group (<i>p</i><0.05). The case group had higher levels of beta-amyloid, indoxyl sulfate, and PTH, compared to the control group (<i>p</i><0.05). Significant differences were found in vitamin D and indoxyl sulfate levels between the groups with and without cognitive impairment (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>Lower levels of vitamin D and higher levels of indoxyl sulfate were observed in the group with cognitive impairment when compared to the group without cognitive impairment.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"44-47"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Management: Fires, Floods, Hurricanes, Oh My! The Importance of Disaster Planning. 风险管理:火灾、洪水、飓风,哦,我的天!灾害规划的重要性。
Q3 Medicine Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Akemini Kem Isang

This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note: The information and recommendations in this article are applicable to physicians and other health care professionals so "clinician" is used to indicate all treatment team members.

本栏目致力于为读者提供与医疗实践相关的法律风险管理信息。我们诚邀读者提问。答案由 PRMS (www.prms.com) 提供,PRMS 是一家医疗专业责任保险计划管理公司,其服务包括为医疗服务提供者提供风险管理咨询和其他资源,以帮助改善患者治疗效果并降低专业责任风险。本专栏公布的答案仅代表一家风险管理咨询公司的答案。其他风险管理咨询公司或保险公司可能会提供不同的建议,读者应对此加以考虑。本专栏中的信息不构成法律建议。如需法律建议,请联系您的个人律师。注:本文中的信息和建议适用于医生和其他医疗保健专业人员,因此 "临床医生 "用于指所有治疗团队成员。
{"title":"Risk Management: Fires, Floods, Hurricanes, Oh My! The Importance of Disaster Planning.","authors":"Akemini Kem Isang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note: The information and recommendations in this article are applicable to physicians and other health care professionals so \"clinician\" is used to indicate all treatment team members.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"48-49"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review. 截至 2024 年 6 月 1 日正在进行 III 期临床试验的精神科药物概览:系统回顾。
Q3 Medicine Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch

Objective: This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.

Methods: We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords "psychiatric" OR "psychopharm*" AND "medic*" OR "pharm*". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.

Results: As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).

Conclusion: The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.

目的:本系统综述概述了截至 2024 年 6 月 1 日处于开发后期(III 期临床试验)的精神科药物。它详细介绍了这些药物的作用机制、疗效、剂量和不良反应:我们使用关键词 "psychiatric "或 "psychopharm*"和 "medic*",在 PubMed 数据库中检索了截至 2024 年 6 月 1 日发表的精神科药物 III 期临床研究。和 "medic*"或 "pharm*"。我们的研究包括目前正在进行 III 期临床试验的药物,以及已经完成 III 期临床试验但正在等待美国食品药品管理局 (FDA) 批准的药物。我们对确定的研究进行了独立分析,并就纳入本系统综述的药物达成了共识:截至 2024 年 6 月 1 日,共确定了 89 项管线药物试验,其中包括 9 项精神分裂症试验、5 项双相情感障碍试验、25 项抑郁障碍试验、11 项焦虑障碍试验、5 项创伤后应激障碍试验、1 项强迫症试验、2 项进食障碍试验、2 项创伤后应激障碍试验、1 项强迫症试验、2 例进食障碍、2 例睡眠-觉醒障碍、3 例性功能障碍、1 例药物相关和成瘾性障碍、22 例神经认知障碍和 3 例神经发育障碍,特别是注意力缺陷多动障碍(ADHD)。结论截至 2024 年 6 月 1 日,正在研发中的精神科药物在治疗精神障碍方面大有可为。
{"title":"Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.","authors":"Waguih William IsHak, Ashley Meyer, Luiza Freire, Jayant Totlani, Nathalie Murphy, Sabrina Renteria, Mohamed Salem, Tiffany Chang, Rasha Abdelsalam, Rida Khan, Thomas Chandy, Thomas Parrish, Drew Hirsch, Bhumika Patel, Alexander J Steiner, Sarah Kim, Rebecca Hedrick, Robert N Pechnick, Itai Danovitch","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024. It details the mechanisms of action, efficacy, dosing, and adverse effects of these medications.</p><p><strong>Methods: </strong>We searched the PubMed database for Phase III studies of psychiatric medications published until June 1, 2024, using the keywords \"psychiatric\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*\". Our review encompassed medications currently undergoing Phase III clinical trials and those that have completed Phase III but are awaiting approval from the United States Food and Drug Administration (FDA). We independently analyzed the identified studies and reached a consensus on the medications to be included in this systematic review.</p><p><strong>Results: </strong>As of June 1, 2024, a total of 89 pipeline drug trials were identified, including nine for schizophrenia, five for bipolar disorders, 25 for depressive disorders, 11 for anxiety disorders, five for post-traumatic stress disorder (PTSD), one for obsessive compulsive disorder (OCD), two for eating disorders, two for sleep-wake disorders, three for sexual dysfunctions, one for substance-related and addictive disorders, 22 for neurocognitive disorders, and three for neurodevelopmental disorders, specifically attention deficit hyperactivity disorder (ADHD).</p><p><strong>Conclusion: </strong>The psychiatric medications in the pipeline as of June 1, 2024, demonstrate significant promise in treating psychiatric disorders.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"27-47"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activation of the serotonergic neurotransmission is a double-edged sword in the treatment of burning mouth syndrome. 激活血清素能神经递质是治疗灼口综合征的一把双刃剑。
Q3 Medicine Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Takahiko Nagamine
{"title":"Activation of the serotonergic neurotransmission is a double-edged sword in the treatment of burning mouth syndrome.","authors":"Takahiko Nagamine","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Literary Prescriptions: Applying Bibliotherapy in a Psychotherapeutic Context. 文学处方:在心理治疗背景下应用书目疗法。
Q3 Medicine Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Andrew B Correll, Terry L Correll, Matthew C Correll

Bibliotherapy, a relatively underutilized lifestyle intervention in psychotherapy, is a unique cost-effective avenue of treatment that empowers patients by integrating therapeutic reading into their treatment plan. This approach strategically uses empirically validated cognitive-behavioral and self-help literature to facilitate the application of therapeutic topics outside of psychotherapy sessions. Bibliotherapy's range of administration styles highlights its potential as an adjunct to medication, psychotherapy, and/or healthy lifestyle interventions in a comprehensive treatment plan. Most meta-analyses conducted so far regarding bibliotherapy in a clinical setting consist of studies that use minimal patient interaction via short phone calls or emails. Despite this, meta-analyses show medium-to-large effect sizes that are comparable to traditional psychotherapy modalities for common disorders, most notably depression. This article explores the practical implementation of bibliotherapy research via an example psychotherapy session with a patient who has a diagnosis of major depressive disorder (MDD). An evidence-based reading list is proposed alongside a decision tree and actionable clinical insights for the effective implementation of bibliotherapy.

书目疗法是心理疗法中一种利用率相对较低的生活方式干预方法,它是一种独特的、具有成本效益的治疗途径,通过将治疗性阅读融入治疗计划,增强患者的能力。这种方法策略性地使用经过经验验证的认知行为和自助文献,以促进治疗主题在心理治疗疗程之外的应用。书目疗法的多种管理方式凸显了它在综合治疗计划中作为药物治疗、心理治疗和/或健康生活方式干预的辅助手段的潜力。迄今为止,有关临床环境中书目疗法的大多数荟萃分析都是通过简短的电话或电子邮件与患者进行最少互动的研究。尽管如此,荟萃分析表明,在常见疾病(尤其是抑郁症)的治疗方面,荟萃分析表明了与传统心理治疗模式相当的中大型效应。本文通过一个与被诊断为重度抑郁障碍(MDD)的患者进行心理治疗的实例,探讨了书目疗法研究的实际应用。为有效实施书目疗法,本文提出了一份循证阅读清单,同时还提供了决策树和可操作的临床见解。
{"title":"Literary Prescriptions: Applying Bibliotherapy in a Psychotherapeutic Context.","authors":"Andrew B Correll, Terry L Correll, Matthew C Correll","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bibliotherapy, a relatively underutilized lifestyle intervention in psychotherapy, is a unique cost-effective avenue of treatment that empowers patients by integrating therapeutic reading into their treatment plan. This approach strategically uses empirically validated cognitive-behavioral and self-help literature to facilitate the application of therapeutic topics outside of psychotherapy sessions. Bibliotherapy's range of administration styles highlights its potential as an adjunct to medication, psychotherapy, and/or healthy lifestyle interventions in a comprehensive treatment plan. Most meta-analyses conducted so far regarding bibliotherapy in a clinical setting consist of studies that use minimal patient interaction via short phone calls or emails. Despite this, meta-analyses show medium-to-large effect sizes that are comparable to traditional psychotherapy modalities for common disorders, most notably depression. This article explores the practical implementation of bibliotherapy research via an example psychotherapy session with a patient who has a diagnosis of major depressive disorder (MDD). An evidence-based reading list is proposed alongside a decision tree and actionable clinical insights for the effective implementation of bibliotherapy.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuropsychological Functioning Among Patients with OCD in Asian Countries: A Systematic Review. 亚洲国家强迫症患者的神经心理功能:系统回顾
Q3 Medicine Pub Date : 2024-09-01 eCollection Date: 2024-07-01
Uzma Ilyas, Sabeela Saher, Ayesha Ahmad Khan, Anam Shahid, Zarmin Tariq

Objective: This systematic review aimed to identify the effect of obsessive compulsive disorder (OCD) on cognitive processes, such as memory, executive functioning, and cognitive flexibility, among the adult populations of Asian countries.

Methods: The systematic review progressed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It is comprised of articles sourced from Asian countries published from 2018 to 2022, and literature about deficits in memory, executive functioning, and cognitive flexibility in the OCD population was gathered from five electronic databases, including Google Scholar, PubMed, Research Gate, Science Direct, and Wiley Online Library. Full-text impact factor articles in the English language were considered in this study.

Results: This study screened 44 articles; five were included based on the eligibility criteria for the present systematic review. Four articles found cognitive deficits in the domains of executive functioning, memory, and cognitive flexibility among patients with OCD, whereas results of one article showed normal cognitive performance of the patients. Demographic variables showed no significant differences between patients with OCD and healthy controls.

Conclusion: This systematic review indicated deficits specifically in the cognitive functioning and flexibility of patients with OCD. Despite a noticeable prevalence of OCD in Asian countries, the literature on correlates and neurological functioning is scarce. Further studies are required to examine the effects on the larger population and provide knowledge in those countries and areas where people are suffering because of minimal knowledge regarding OCD.

目的:本系统综述旨在确定强迫症对亚洲国家成年人的认知过程(如记忆、执行功能和认知灵活性)的影响:本系统综述旨在确定强迫症(OCD)对亚洲国家成年人的记忆、执行功能和认知灵活性等认知过程的影响:本系统综述根据系统综述和元分析首选报告项目(PRISMA)指南进行。它由2018年至2022年发表的来自亚洲国家的文章组成,从谷歌学术、PubMed、Research Gate、Science Direct和Wiley Online Library等五个电子数据库中收集了有关强迫症人群记忆力、执行功能和认知灵活性缺陷的文献。本研究考虑的是具有影响因子的英文全文:本研究筛选了 44 篇文章,根据本系统综述的资格标准,有 5 篇文章被纳入其中。四篇文章发现强迫症患者在执行功能、记忆力和认知灵活性方面存在认知缺陷,而一篇文章的结果显示患者的认知表现正常。人口统计学变量显示,强迫症患者与健康对照组之间没有明显差异:本系统综述表明,强迫症患者在认知功能和灵活性方面存在缺陷。尽管强迫症在亚洲国家的发病率很高,但有关其相关因素和神经功能的文献却很少。我们需要进一步研究强迫症对更多人群的影响,并为那些因对强迫症知之甚少而饱受折磨的国家和地区提供相关知识。
{"title":"Neuropsychological Functioning Among Patients with OCD in Asian Countries: A Systematic Review.","authors":"Uzma Ilyas, Sabeela Saher, Ayesha Ahmad Khan, Anam Shahid, Zarmin Tariq","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review aimed to identify the effect of obsessive compulsive disorder (OCD) on cognitive processes, such as memory, executive functioning, and cognitive flexibility, among the adult populations of Asian countries.</p><p><strong>Methods: </strong>The systematic review progressed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. It is comprised of articles sourced from Asian countries published from 2018 to 2022, and literature about deficits in memory, executive functioning, and cognitive flexibility in the OCD population was gathered from five electronic databases, including Google Scholar, PubMed, Research Gate, Science Direct, and Wiley Online Library. Full-text impact factor articles in the English language were considered in this study.</p><p><strong>Results: </strong>This study screened 44 articles; five were included based on the eligibility criteria for the present systematic review. Four articles found cognitive deficits in the domains of executive functioning, memory, and cognitive flexibility among patients with OCD, whereas results of one article showed normal cognitive performance of the patients. Demographic variables showed no significant differences between patients with OCD and healthy controls.</p><p><strong>Conclusion: </strong>This systematic review indicated deficits specifically in the cognitive functioning and flexibility of patients with OCD. Despite a noticeable prevalence of OCD in Asian countries, the literature on correlates and neurological functioning is scarce. Further studies are required to examine the effects on the larger population and provide knowledge in those countries and areas where people are suffering because of minimal knowledge regarding OCD.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 7-9","pages":"22-26"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Innovations in clinical neuroscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1